With All Chips On Phase II Antibody Conjugate, CuraGen Eyes Strategic Options
This article was originally published in The Pink Sheet Daily
Executive Summary
Biotech’s cash coffers are well stocked, but out-license of GPNMB-targeting cancer drug – or outright sale of the company – could be next.
You may also be interested in...
2009 Is ImmunoGen’s Make-Or-Break Year
The antibody-drug conjugate company has struggled for validation while supporting itself with partner funds, but a spate of data due this year could spark a turnaround.
2009 Is ImmunoGen’s Make-Or-Break Year
The antibody-drug conjugate company has struggled for validation while supporting itself with partner funds, but a spate of data due this year could spark a turnaround.
Seattle Genetics Moves Antibody-Drug Conjugate Into Phase III For Hodgkin’s Lymphoma
SGN-35 trial kicks off in first quarter under a special protocol assessment, with an NDA filing targeted for 2011.